Reduce MRSA Infection
Rates by Up to 96%1?

Take the first step with Nozin NOVASM Programs.

Get a Free Assessment


* These fields are required.

MRSA / MSSA Colonization Risk Mitigation Programs

Nozin, leaders in developing and implementing MRSA / MSSA risk mitigation programs, introduces NOVASM. A proprietary suite of tools and services, NOVASM programs are guided by experienced consultants and proven to reduce infection risks while improving patient care.

Methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-sensitive Staphylococcus aureus (MSSA) infections are a major component of total healthcare-associated infections (HAIs).

Patients who are colonized with MRSA in the nares are 14 to 20 times more likely to acquire MRSA infection than non-carriers.

NOVASM MRSA / MSSA colonization risk mitigation programs reduce colonization, which reduces infection risk.

Facilities that have adopted the NOVA programs approach are reporting significant outcomes such as:

96%

reduction in MRSA bacteremia hospital-wide2

Advent Health North Pinellas, FL
100%

reduction in total hip and knee SSI2

Wellstar Cobb Hospital, GA
74%

decline in MRSA bacteremia2

Jackson Health System, FL

Visit nozin.com/clinical-outcomes for more data.

How Nozin NOVASM Programs Work

Nozin NOVASM programs are a proprietary suite of analytical tools and services guided by experienced consultants. Built on shared knowledge from hundreds of facility implementations, NOVASM programs are proven to reduce infection risks while improving patient care.

We know that making the change from traditional strategies can be a challenge. Here’s what you can expect when you partner with Nozin NOVASM .

Comprehensive Risk Assessment

  • Detail the extent of colonization in your facility
  • Determine the risk colonization represents
  • Gauge the impact on your facility and potential improvement
  • Analyze efficacy of current protocols

Customized Programs

  • Help design new colonization risk mitigation strategy
  • Define your desired improvement goals
  • Collaboratively design implementation plan to achieve your goals

IMPLEMENTATION AND ONGOING SUPPORT

  • Prepare for and execute a successful implementation and compliance maintenance program
  • Continuous support by the Nozin NOVA team to ensure success

Nozin NOVASM IS POWERED BY THE #1 BRAND IN DAILY PATIENT NASAL DECOLONIZATION

More outcomes data published or presented than for any other nasal antiseptic

15-year safety record

Millions of users

Fast, easy, pleasant application – preferred by staff and patients

Patented Nozaseptin® formula:

  • Kills 99.99% of germs
  • 12-hour persistence

Proprietary Popswab® delivery system

More daily decolonization outcomes data

The right tool for MRSA / MSSA risk mitigation programs

Rechargeable for second nostril application

Schedule your NOVASM Assessment

Facilities that have implemented Nozin NOVASM programs have shown up to $1.4 million annual cost savings2 and up to 60% reduction in PPE use2. Take the first step today.

Get a Free Assessment

Learn More

Evidence counts. See why we’re the leader in daily nasal decolonization.

Download White Paper

Contact Us

Phone

877-669-4648 301-337-2059

Email

[email protected]

1. Arden S. Does Universal Nasal Decolonization with an Alcohol-Based Nasal Antiseptic Reduce Infection Risk and Cost? Open Forum Infect Dis 2019 Oct; 6(Suppl 2): S26.

 

2. Additional references at: https://www.nozin.com/clinical-outcomes.

 

Outcomes reported by actual users. Your results may vary. Nozin® Nasal Sanitizer® antiseptic is for nasal decolonization. No claim is made that it has an effect on any specific disease. ©2020 Global Life Technologies Corp. All rights reserved. Made in USA. Nozin®, Nasal Sanitizer®, Popswab®, NOVA and Nozaseptin® are trademarks of Global Life Technologies Corp. Nozin® Nasal Sanitizer® antiseptic is an OTC topical drug. Patent nos.: nozin.com/patents.